Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 91

Sort by

Sort Order Select

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Blood (2023) 142 (Supplement 1): 6864.

https://doi.org/10.1182/blood-2023-184868

Published: 2023

Journal Articles

When Patients with Plasma Cell Disorders Encountered the Largest Omicron Wave (December 2022) in China: A Real-World Multicenter and Multiregional Study

Xincheng Jiang, Zhen Cai, Xiaoyan Han, Fengyan Jin, Gang An, Jian Hou, Jingsong He, Qingming Wang, Wenjun Wu, Yi Zhao, Songfu Jiang, Shuchan Li, Zhenshu Xu, Gaofeng Zheng, Yang Yang, Qingxiao Chen, Donghua He, Yi Li

Blood (2023) 142 (Supplement 1): 6673.

https://doi.org/10.1182/blood-2023-174224

Published: 2023

Journal Articles

Real-World Treatment Patterns, Discontinuation and Clinical Outcomes in Patients with B-Cell Lymphoproliferative Diseases Treated with BTK Inhibitors in China

Yuting Yan, Rui Lyv, Tingyu Wang, Ying Yu, Yanshan Huang, Wenjie Xiong, Gang An, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 6138.

https://doi.org/10.1182/blood-2023-188862

Published: 2023

Journal Articles

Static and Dynamic Assessment to Identify Ultra-High Risk Multiple Myeloma：Analysis for Patients with Overall Survival No More Than Three Years

Yan Xu, Gang An, Shuhui Deng, Weiwei Sui, Wei Liu, Wenyang Huang, Tingyu Wang, Shuhua Yi, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6701.

https://doi.org/10.1182/blood-2023-189353

Published: 2023

Journal Articles

Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without Daratumumab

Blood (2023) 142 (Supplement 1): 2006.

https://doi.org/10.1182/blood-2023-180809

Published: 2023

Journal Articles

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Wei Liu, Yi Wang, Yan Xu, Chenxing Du, Qi Wang, Tingyu Wang, Wenyang Huang, Shuaishuai Zhang, Shuhua Yi, Yuting Yan, Tengteng Yu, Weiwei Sui, Gang An, Rui Lyu, Huimin Liu, Wenjie Xiong, Mingwei Fu, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6232.

https://doi.org/10.1182/blood-2023-185669

Published: 2023

Journal Articles

Monitoring Minimal Residual Disease in Patients with Multiple Myeloma By Tracking Serum M-Protein Using Mass Spectrometry

Huishou Fan, Bing Wang, Lugui Qiu, Bin Ma, Gang An

Blood (2023) 142 (Supplement 1): 1920.

https://doi.org/10.1182/blood-2023-181761

Published: 2023

Journal Articles

The Specific Transcriptional Signature and Clonal Selection of MGUS-like Profile Predict an Exceptionally Favorable Prognosis in Patients with Newly-Diagnosed Multiple Myeloma

Wenqiang Yan, Chen Qiu, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Dehui Zou, Weiping Yuan, Lugui Qiu, Gang An

Blood (2023) 142 (Supplement 1): 879.

https://doi.org/10.1182/blood-2023-180351

Published: 2023

Journal Articles

The Prognostic Impact of Measurable Residual Disease Dynamics in Mantle Cell Lymphoma

Yanshan Huang, Yuting Yan, Ying Yu, Li Yuxi, Rui Lv, Tingyu Wang, Wenjie Xiong, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2023-188881

Published: 2023

Journal Articles

Development and Validation of an Individualized and Weighted Prognostic Model in Patients with Newly Diagnosed Multiple Myeloma

Wenqiang Yan, Xuehan Mao, David E. Mery, Yan Xu, Weiwei Sui, Shuhui Deng, Dehui Zou, John D Shaughnessy, Jr, Kenneth C. Anderson, Fenghuang Zhan, Lugui Qiu, Gang An

Blood (2023) 142 (Supplement 1): 1967.

https://doi.org/10.1182/blood-2023-182598

Published: 2023

Journal Articles

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Li Yuxi, Ying Yu, Yanshan Huang, Rui Cui, Jingwen Sun, Rui Lyu, Tingyu Wang, Wenjie Xiong, Yuting Yan, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 1649.

https://doi.org/10.1182/blood-2023-186068

Published: 2023

Journal Articles

Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in MRD Clones in Multiple Myeloma through Single-Cell Sequencing

Jian Cui, Xiaoyun Li, Shuhui Deng, Lugui Qiu, Xin Gao, Gang An

Blood (2023) 142 (Supplement 1): 4667.

https://doi.org/10.1182/blood-2023-179735

Published: 2023

Journal Articles

Hyposecretory Progression Pattern Indicates Inferior Survival of Multiple Myeloma

Jingyu Xu, Wenqiang Yan, Lingna Li, Chenxing Du, Lugui Qiu, Gang An

Blood (2023) 142 (Supplement 1): 1955.

https://doi.org/10.1182/blood-2023-178217

Published: 2023

Journal Articles

The Incidence, Clinical Application and Prognostic Significance of MYD88 and CXCR4 Mutation in Chinese Patients with Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia

Ying Yu, Yuting Yan, Jun Wang, Wenjie Xiong, Yao Yao, Yanshan Huang, Rui Lyu, Tingyu Wang, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Zhijian Xiao, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 6089.

https://doi.org/10.1182/blood-2023-188786

Published: 2023

Journal Articles

Phenotype Molding of Monocytes in the Multiple Myeloma Microenvironment

Jian Cui, Jingwei Wang, Lugui Qiu, Gang An

Blood (2023) 142 (Supplement 1): 6595.

https://doi.org/10.1182/blood-2023-179031

Published: 2023

Journal Articles

Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Asian Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of the Phase 3 Octans Study

Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Robin Carson, Rui Liu, Lingling Wang, Man Zhao, Xi Chen, Canchan Cui, Jian Hou, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 3388.

https://doi.org/10.1182/blood-2023-181063

Published: 2023

Journal Articles

Treatment Patterns and Outcomes in Patients with Multiple Myeloma Who Received Ixazomib and in Patients with Triple-Class Refractory Multiple Myeloma: A Retrospective, Observational, Real-World Historical Database Analysis Study from China

Gang An, Lin Li, Sha Liu, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6710.

https://doi.org/10.1182/blood-2023-182729

Published: 2023

Journal Articles

Is the Second Revision of the International Staging System (R2-ISS) for Multiple Myeloma Valid in a Real-World Population from China?

Wenqiang Yan, Lingna Li, Huishou Fan, Jingyu Xu, Shuhui Deng, Weiwei Sui, Yan Xu, Dehui Zou, Lugui Qiu, Gang An

Blood (2022) 140 (Supplement 1): 7255–7256.

https://doi.org/10.1182/blood-2022-158751

Published: 2022

Journal Articles

Zanubrutinib Plus Ixazomib and Dexamethasone for Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Prospective, Phase II Study

Ying Yu, ShuHua Yi, Xiong Wenjie, Tingyu Wang, Yuting Yan, Wei Liu, Weiwei Sui, Gang An, Yan Xu, Huimin Liu, Wenyang Huang, Dehui Zou, Lugui Qiu

Blood (2022) 140 (Supplement 1): 3587–3588.

https://doi.org/10.1182/blood-2022-162338

Published: 2022

Journal Articles

Impact of Neoplastic Plasma Cells in the Stem Cell Collection on Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

Jingyu Xu, Lingna Li, Wenqiang Yan, Huishou Fan, Jiahui Liu, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu, Gang An

Blood (2022) 140 (Supplement 1): 10011–10012.

https://doi.org/10.1182/blood-2022-165889

Published: 2022

NARROW

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

When Patients with Plasma Cell Disorders Encountered the Largest Omicron Wave (December 2022) in China: A Real-World Multicenter and Multiregional Study

Real-World Treatment Patterns, Discontinuation and Clinical Outcomes in Patients with B-Cell Lymphoproliferative Diseases Treated with BTK Inhibitors in China

Static and Dynamic Assessment to Identify Ultra-High Risk Multiple Myeloma：Analysis for Patients with Overall Survival No More Than Three Years

Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without Daratumumab

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Monitoring Minimal Residual Disease in Patients with Multiple Myeloma By Tracking Serum M-Protein Using Mass Spectrometry

The Specific Transcriptional Signature and Clonal Selection of MGUS-like Profile Predict an Exceptionally Favorable Prognosis in Patients with Newly-Diagnosed Multiple Myeloma

The Prognostic Impact of Measurable Residual Disease Dynamics in Mantle Cell Lymphoma

Development and Validation of an Individualized and Weighted Prognostic Model in Patients with Newly Diagnosed Multiple Myeloma

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in MRD Clones in Multiple Myeloma through Single-Cell Sequencing

Hyposecretory Progression Pattern Indicates Inferior Survival of Multiple Myeloma

The Incidence, Clinical Application and Prognostic Significance of MYD88 and CXCR4 Mutation in Chinese Patients with Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia

Phenotype Molding of Monocytes in the Multiple Myeloma Microenvironment

Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Asian Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of the Phase 3 Octans Study

Treatment Patterns and Outcomes in Patients with Multiple Myeloma Who Received Ixazomib and in Patients with Triple-Class Refractory Multiple Myeloma: A Retrospective, Observational, Real-World Historical Database Analysis Study from China

Is the Second Revision of the International Staging System (R2-ISS) for Multiple Myeloma Valid in a Real-World Population from China?

Zanubrutinib Plus Ixazomib and Dexamethasone for Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Prospective, Phase II Study

Impact of Neoplastic Plasma Cells in the Stem Cell Collection on Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only